HVTN 706 - A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of a Heterologous Vaccine Regimen of Ad26.Mos4.HIV and Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals who Have Sex with Cis-gender Men and/or Transgender Individuals
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: Healthy | HIV
Age: Between 18 - 59 Years
Gender: Male or Female
Other eligibility criteria:
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required